Project Grant 20236701739058
- Grant Award Summary The University of Colorado-Denver received a $234,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 15, 2025, with a completion date of September 14, 2027. This award funds biomedical research investigating the role of AIOLOS, a transcriptional repressor protein, in T cell-mediated pathogenesis of inflammatory...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $2.08 million Project Grant to the University of Colorado-Denver on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The four-year award, extending through September 2029, funds basic biomedical research investigating the relationship between Paneth cell mitochondrial dysfunction and intestinal homeostasis in...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $381,992 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective June 18, 2025, with completion by December 31, 2026. The award funds research investigating the role of adrenomedullin 2 (ADM2) in regulating innate lymphoid cell responses to control intestinal...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $1.71 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded July 2, 2025, with completion targeted for April 30, 2029. The project, titled "AGR2 Regulates Host-Microbe Responses in Crohn's Disease," will deliver fundamental and translational...
- Federal Project Grant Award Summary Boston University Medical Campus received a $703,748 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 1, 2026, through February 28, 2030. The grant funds basic biomedical research aimed at elucidating the role of bacterial polyphosphates in exacerbating intestinal inflammation and inflammatory bowel...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of North Carolina at Chapel Hill a $1.55 million Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) beginning July 1, 2025, with completion targeted for April 30, 2029. The award funds development of a novel therapeutic approach using bioengineered probiotic yeast (Saccharomyces boulardii) to treat inflammatory...
- This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York $587,470 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on March 16, 2026. This Project Grant supports basic biomedical research aimed at elucidating the molecular mechanisms of inflammatory bowel disease (IBD), with completion targeted for January 31, 2030. The research...
- Federal Grant Award Summary Nous Biosciences Inc. received a $716,078 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 3, 2025, with a completion date of August 31, 2026. The award funds preclinical research on a novel combination therapeutic approach for treating inflammatory bowel disease (IBD), specifically examining the...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded University of Maryland, Baltimore $3.34 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a four-year Project Grant beginning September 1, 2025, and concluding August 31, 2029. This award supports mechanistic research investigating the causal relationship between periodontitis, a prevalent oral infection, and inflammatory bowel...
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** INFLAMMATORY BOWEL DISEASES (IBD) ARE AN INCREASINGLY IMPORTANT GLOBAL HEALTH PROBLEM; OVER 850,000 PEOPLE IN THE UNITED STATES ARE EFFECTED ANNUALLY, AND THE WORLDWIDE INCIDENCE OF IBD HAS INCREASED SINCE 1990. IBD ARE CHARACTERIZED BY CHRONIC INFLAMMATION AND ULCERATION OF THE COLON, ABDOMINAL PAIN, WEIGHT LOSS, BLOODY DIARRHEA, AND AN INCREASED RISK OF A NUMBER OF OTHER DISEASES, INCLUDING COLORECTAL CANCER AND TYPE 2 DIABETES. WHILE DIETARY, DRUG, AND BIOLOGICAL THERAPIES HAVE BEEN USEFUL IN THE MANAGEMENT OF IBD, THE ONLY 'CURATIVE' TREATMENT CURRENTLY AVAILABLE IS SURGICAL RESECTIONING OF THE COLON. IN ADDITION TO NOT BEING TRULY CURATIVE, SURGICAL OPTIONS HAVE SIGNIFICANT SIDE-EFFECTS, INCLUDING INCREASED RISK OF INFECTION. CHRONIC INFLAMMATION HAS BEEN SHOWN TO UNDERLIE IBD, AS WELL AS OTHER CHRONIC DISEASES, INCLUDING LIVER DISEASE AND DIABETES. AND THE ARYL HYDROCARBON RECEPTOR (AHR) IS A CRUCIAL REGULATOR IN THE GASTROINTESTINAL TRACT, PROMOTING BALANCE IN THE GUT WHILE LOWERING INFLAMMATION AND PROTECTING AGAINST NUMEROUS DISEASES.BOTANICALS CONTAIN HUNDREDS OF DIFFERENT PHYTOCHEMICALS, AND HAVE BEEN SHOWN TO HAVE BENEFICIAL HEALTH EFFECTS. AND CONSUMPTION OF THESE FOODS (FRUITS, VEGETABLES, NUTS, FUNGI, ETC.) HAS BEEN LINKED TO IMPROVED GASTROINTESTINAL HEALTH AND LOWER INFLAMMATION. A DIVERSE ARRAY OF FOODS, INCLUDING BROCCOLI, CORN, MUSHROOMS, CARROTS, BERRIES, ETC., HAVE DEMONSTRATED ACTIVITY IN ACTIVATING THE AHR IN PRELIMINARY STUDIES. HOWEVER, THE CHEMICAL AGENTS OF THESE FOODS THAT ARE RESPONSIBLE FOR THIS ACTIVITY REMAIN UNKNOWN. USING OUR INNOVATIVE CHEMICAL PROFILING AND DATA MODELING APPROACHES, WE WILL BE ABLE TO TEASE APART THE DIFFERING CHEMICAL SIGNATURES AND IDENTIFY WHICH MOLECULES ARE ABLE TO ACTIVATE THE AHR. WE WILL BE INVESTIGATING INTERACTIONS AT THE INTERFACE OF FOOD, NUTRITION, THE GUT MICROBIOME, AND THEIR DOWNSTREAM EFFECTS ON CHRONIC HUMAN DISEASE. USING BOTH CELLULAR AND MOUSE MODELS, WE WILL BE ABLE TO ASCERTAIN THEIR EFFECTS ON THE AHR AS WELL AS SUBSEQUENT EFFECTS ON THE GASTROINTESTINAL SYSTEM, INCLUDING THEIR ABILITY TO MITIGATE INFLAMMATORY BOWEL DISEASES.THIS PROJECT WILL PROVIDE A GREATER UNDERSTANDING OF THE MECHANISMS THAT UNDERLIE DIETARY PROTECTION AGAINST INFLAMMATORY GASTROINTESTINAL DISEASES. IT WILL LEAD TO A GREATER UNDERSTANDING OF THE BOTANICAL PHYTOCHEMICALS AND THEIR AHR ACTIVITY, AND THE DATA CAN BE USED TO GUIDE DIETARY RECOMMENDATIONS THAT MODULATE AHR ACTIVITY TO IMPROVE HUMAN GASTROINTESTINAL HEALTH AND COMBAT CHRONIC GI DISEASES. MOREOVER, THESE ENDEAVORS WILL ALLOW US TO PROVIDE PREDICTIVE MODELS AND TO ENHANCE THE ABILITY TO DISCRIMINATE BETWEEN SPECIES OR CULTIVARS AND EVEN PREDICT THE CULTIVAR AND BIOACTIVITY OF UNKNOWN BOTANICAL PRODUCT. THESE DATA WILL ALSO BENEFIT BOTANICAL USERS (SUPPLEMENT MANUFACTURERS AND CONSUMERS) BY PROVIDING A MORE NUANCED UNDERSTANDING OF THE RELATIONSHIP BETWEEN PHYTOCHEMISTRY AND BIOACTIVITY OF VEGETABLE CROPS AND BOTANICALS. WHILE THE P,RESENT STUDY IS FOCUSED ON A LIMITED SELECTION OF MODEL CROPS, THE INNOVATIVE APPROACHES ARE APPLICABLE TO ANY NUTRITIONAL OR MEDICINAL PLANT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $638.0k | 1/23/23 |